Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

NARecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

February 22, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

June 30, 2026

Conditions

AMLRefractoryRelapsed

Interventions

DRUG

Ivosidenib,Venetoclax,gilteritinib,Selinexor

if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)

Trial Locations (1)

RECRUITING

Blood Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER